These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 19597960)

  • 1. Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS).
    Jones SA; Almássy Z; Beck M; Burt K; Clarke JT; Giugliani R; Hendriksz C; Kroepfl T; Lavery L; Lin SP; Malm G; Ramaswami U; Tincheva R; Wraith JE;
    J Inherit Metab Dis; 2009 Aug; 32(4):534-43. PubMed ID: 19597960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS).
    Burton BK; Jego V; Mikl J; Jones SA
    J Inherit Metab Dis; 2017 Nov; 40(6):867-874. PubMed ID: 28887757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS).
    Burton BK; Whiteman DA;
    Mol Genet Metab; 2011 Jun; 103(2):113-20. PubMed ID: 21439875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS).
    Muenzer J; Botha J; Harmatz P; Giugliani R; Kampmann C; Burton BK
    Orphanet J Rare Dis; 2021 Oct; 16(1):456. PubMed ID: 34717704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS).
    Muenzer J; Giugliani R; Scarpa M; Tylki-Szymańska A; Jego V; Beck M
    Orphanet J Rare Dis; 2017 Oct; 12(1):161. PubMed ID: 28974237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
    Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
    Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study.
    Guffon N; Heron B; Chabrol B; Feillet F; Montauban V; Valayannopoulos V
    Orphanet J Rare Dis; 2015 Apr; 10():43. PubMed ID: 25887606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.
    Wraith JE; Scarpa M; Beck M; Bodamer OA; De Meirleir L; Guffon N; Meldgaard Lund A; Malm G; Van der Ploeg AT; Zeman J
    Eur J Pediatr; 2008 Mar; 167(3):267-77. PubMed ID: 18038146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry.
    Muenzer J; Jones SA; Tylki-Szymańska A; Harmatz P; Mendelsohn NJ; Guffon N; Giugliani R; Burton BK; Scarpa M; Beck M; Jangelind Y; Hernberg-Stahl E; Larsen MP; Pulles T; Whiteman DAH
    Orphanet J Rare Dis; 2017 May; 12(1):82. PubMed ID: 28464912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Causes of death and clinical characteristics of 34 patients with Mucopolysaccharidosis II in Taiwan from 1995-2012.
    Lin HY; Chuang CK; Huang YH; Tu RY; Lin FJ; Lin SJ; Chiu PC; Niu DM; Tsai FJ; Hwu WL; Chien YH; Lin JL; Chou YY; Tsai WH; Chang TM; Lin SP
    Orphanet J Rare Dis; 2016 Jun; 11(1):85. PubMed ID: 27349225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II.
    Yee KS; Lewis S; Evans E; Romano C; Alexanderian D
    Orphanet J Rare Dis; 2024 Mar; 19(1):110. PubMed ID: 38462612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II.
    Żuber Z; Różdżyńska-Świątkowska A; Jurecka A; Tylki-Szymańska A
    PLoS One; 2014; 9(1):e85074. PubMed ID: 24454794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
    Wraith JE
    Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
    Whiteman DA; Kimura A
    Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2014 Jan; (1):CD008185. PubMed ID: 24399699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008185. PubMed ID: 22071845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Early response to idursulfase in a 31-year old male patient with Hunter syndrome].
    Pérez-Calvo J; Bergua Sanclemente I; López Moreno MJ; Torralba Cabeza MÁ; Amores Arriaga B
    Rev Clin Esp; 2011; 211(7):e42-5. PubMed ID: 21524741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years.
    Tomanin R; Zanetti A; D'Avanzo F; Rampazzo A; Gasparotto N; Parini R; Pascarella A; Concolino D; Procopio E; Fiumara A; Borgo A; Frigo AC; Scarpa M
    Orphanet J Rare Dis; 2014 Sep; 9():129. PubMed ID: 25231261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome).
    Sohn YB; Cho SY; Park SW; Kim SJ; Ko AR; Kwon EK; Han SJ; Jin DK
    Orphanet J Rare Dis; 2013 Mar; 8():42. PubMed ID: 23497636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS).
    Jones SA; Parini R; Harmatz P; Giugliani R; Fang J; Mendelsohn NJ;
    Mol Genet Metab; 2013 May; 109(1):41-8. PubMed ID: 23537841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.